

# Cheng Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11337658/publications.pdf>

Version: 2024-02-01

20  
papers

1,264  
citations

471509

17  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites. <i>Molecular Pharmacology</i> , 2007, 72, 592-603.	2.3	143
2	Rapid Identification of P-glycoprotein Substrates and Inhibitors. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1976-1984.	3.3	136
3	Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids. <i>Pharmaceutical Research</i> , 2003, 20, 1794-1803.	3.5	112
4	Pharmacophore-based discovery of ligands for drug transporters. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1431-1450.	13.7	101
5	Molecular Determinants of Substrate/Inhibitor Binding to the Human and Rabbit Renal Organic Cation Transporters hOCT2 and rbOCT2. <i>Molecular Pharmacology</i> , 2005, 67, 1067-1077.	2.3	96
6	Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 533-541.	2.5	90
7	Plasma Protein Binding of Challenging Compounds. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2627-2636.	3.3	78
8	A Ligand-Based Approach To Identify Quantitative Structure-Activity Relationships for the Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3765-3776.	6.4	71
9	In Vitro and Pharmacophore-Based Discovery of Novel hPEPT1 Inhibitors. <i>Pharmaceutical Research</i> , 2005, 22, 512-517.	3.5	68
10	Computational approaches to modeling drug transporters. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 411-424.	4.0	67
11	Topology Scanning and Putative Three-Dimensional Structure of the Extracellular Binding Domains of the Apical Sodium-Dependent Bile Acid Transporter (SLC10A2). <i>Biochemistry</i> , 2004, 43, 11380-11392.	2.5	62
12	Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure. <i>Pharmaceutical Research</i> , 2007, 24, 2249-2262.	3.5	61
13	In silico strategies for modeling membrane transporter function. <i>Drug Discovery Today</i> , 2005, 10, 663-671.	6.4	39
14	Quantitative PK-PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans. <i>AAPS Journal</i> , 2011, 13, 565-575.	4.4	36
15	Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4476-4504.	6.4	35
16	Application of data mining approaches to drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1409-1430.	13.7	30
17	The Development and Validation of a Computational Model to Predict Rat Liver Microsomal Clearance. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2857-2867.	3.3	18
18	Computational Modeling of Drug Disposition. , 2006, , 495-512.		5

#	ARTICLE	IF	CITATIONS
19	An exposureâ€“response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation. <i>Xenobiotica</i> , 2017, 47, 673-681.	1.1	5
20	Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition. <i>Molecular Pharmacology</i> , 2018, 94, 823-833.	2.3	5